DNTH · Dianthus Therapeutics, Inc. /DE/ · Metrics
$78.75
+4.21 (+5.65%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 4, 2026
The latest filing states the doubt was alleviated.
“In accordance with Accounting Standards Update No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements were issued (the "issuance date") As of the issuance date, the Company expects that its existing cash, cash equivalents and investments on hand will be sufficient to fund its obligations as they become due for at least twelve months beyond the issuance date.”View the 10-Q filed Aug 4, 2026
Market Cap
$4.40B
Shares
55.93M
Volume · Oct 20
1.87M
Avg daily vol (3M)
822.38K
DNTH metrics
67 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$78.75
Market cap
$4.40B
Price action
20 metricsPrice change (1W)
-8.6%
Price change (30D)
-22.7%
Price change (3M)
-26.2%
Price change (6M)
-18.9%
Price change (YTD)
+80.9%
Price change (1Y)
+109.1%
Trailing year
Price change (5Y)
-27.0%
52-week high
$115.96
52-week low
$32.92
Change from 52-week high
-35.7%
Change from 52-week low
+126.4%
Annualized volatility
61.0%
Annualized volatility (3M)
43.1%
Beta
1.0
RSI (14D)
23.0
Price vs SMA 50
-24.4%
Price vs SMA 200
-10.4%
Avg volume (3M)
806,571
Relative volume
1.2
Average dollar volume
$79.68M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
55.93M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
2,047.8×
reciprocal yield 0.0%
P / book
3.6
reciprocal yield 28.1%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.6%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
764.5×
reciprocal yield 0.1%
EV / revenue historical average (5Y)
764.5×
reciprocal yield 0.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-03-09
Profitability
9 metricsGross margin
—
Operating margin
-8,739.3%
Trailing 12 months
Net margin
-7,973.3%
Gross profit (TTM)
—
Operating profit (TTM)
−$217.84M
Net income (TTM)
−$192.25M
Trailing 12 months
Diluted EPS (TTM)
$-4.25
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-78.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.04M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+56.4%
Year over year · more shares
Revenue CAGR (3Y)
-31.8%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-16.4%
Return on assets
-15.8%
Debt / equity
0.0
Current ratio
26.1
EBITDA (TTM)
−$5.89M
Free cash flow (TTM)
—
Quick ratio
26.1
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$886.81M
Latest balance sheet
Cash & equivalents
$110.55M
Total assets
$1.21B
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$155.38M
Capital expenditures (TTM)
$403,000
R&D (TTM)
$175.60M
SG&A (TTM)
—
Stock compensation (TTM)
$34.27M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
272
13F filer change QoQ
+29
Institutional ownership
118.4%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+2.0%
Holder tenure
7.2
Price vs estimated holder cost
+110.5%
Ownership (registered funds)
1 metricsIndex-fund ownership
13.2%
Short interest
3 metricsShort interest
16.3%
Latest settlement · 8.3 days to cover
Days to cover
8.3d
Short-squeeze score
71 / 100
Insider activity
2 metricsNet insider buying (90D)
−$26.12M
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1690585
CUSIP
252828108
13F (30d)
12 filings
12 filers
Visit website
Investor relations